Advertisement

Quality of Life Research

, Volume 25, Issue 10, pp 2457–2465 | Cite as

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols

  • Rebecca Mercieca-Bebber
  • Michael Friedlander
  • Peey-Sei Kok
  • Melanie Calvert
  • Derek Kyte
  • Martin Stockler
  • Madeleine T. King
Review

Abstract

Purpose

Patient-reported outcomes (PROs) provide the patient’s perspective of the impact of treatment. Evidence suggests that PRO content of randomised controlled trials (RCTs) protocols is generally sub-optimal. This study aimed to describe and evaluate the PRO-specific content of ovarian cancer RCT protocols.

Methods

Published, phase III, ovarian cancer RCTs with PRO endpoints were identified following a systematic search of Medline and Cochrane databases (Jan 2000 to Feb 2016). Corresponding RCT protocols were downloaded (if published) or obtained by contacting authors. Two investigators independently assessed adherence of PRO-specific content of included protocols to a checklist of 58 recommended PRO protocol items currently being developed by the International Society for Quality of Life Research. Discrepancies were resolved with a third investigator.

Results

Of 41 eligible trials identified, 26 protocols were assessed (developed 1995–2010). We were unable to obtain the remaining 15 protocols. Protocols addressed a mean of 28 % PRO checklist items (range 8–66 %). Fifteen (58 % of assessed protocols) provided a rationale for PRO assessment, 8 (31 %) described a PRO objective, 24 (92 %) included a PRO assessment schedule, but only 6 (23 %) justified timing of PRO assessments. Twelve protocols (46 %) provided staff data collection instructions, 4 (15 %) included plans for monitoring PRO compliance, and 16 (62 %) included a PRO analysis plan.

Conclusions

On average, protocols addressed less than one-third of PRO protocol checklist items. In some cases, key guidance regarding PRO administration was lacking, which may lead to inconsistent and sub-optimal PRO methodology. Efforts are needed to improve PRO protocol content in cancer trials.

Keywords

Quality of life Patient-reported outcomes Protocol checklist Ovarian cancer Clinical trials as topic Guideline adherence 

Notes

Acknowledgments

We are grateful to the Gynaecologic Cancer Inter-Group (GCIG) Symptom Benefit Working Group (SBWG), ImPROVeD Contributor’s Group leaders Professors Michael Friedlander, Felix Hilpert and Florence Joly, and to RCT investigators for providing access to trial protocols; specifically (in alphabetical order), D.K. Armstrong, J. Berek, N. Colombo, M. Bookman, M. Brady, J. Bryce, A. du Bois, G. Elser, A. Harkin, S. Kaye, J. Ledermann, K. Lindemann, B. Monk, T. Perren, M. Piccart, S. Pignata, J. Pfisterer, E. Pujade-Lauraine, N. Reed, G. Rustin, J. Sehouli, P. Vasey, and I. Vergote. We also acknowledge F. Roncolato and A. Long for their assistance identifying eligible trials and the International Society for Quality of Life Research Best Practices for PROs Protocol Checklist Taskforce for their contribution to developing the PRO Protocol Checklist.

Funding

This project did not receive specific grant funding. RMB is supported by Sydney Catalyst courtesy of the Cancer Institute NSW. MK is supported by the Australian Government courtesy of Cancer Australia.

Compliance with ethical standards

Conflicts of interest

None.

Ethics

This article is an analysis of PRO-specific content of RCT protocols. It did not involve direct study of human participants, and therefore, human ethics approval was not required.

Informed consent

This article is an analysis of PRO-specific content of RCT protocols. It did not involve direct study of human participants, and therefore, informed consent was not required.

Supplementary material

11136_2016_1339_MOESM1_ESM.docx (26 kb)
Search strategy (DOCX 26 kb)
11136_2016_1339_MOESM2_ESM.docx (21 kb)
PRO protocol checklist (DOCX 21 kb)
11136_2016_1339_MOESM3_ESM.docx (76 kb)
Scatterplot of total PRO protocol checklist scores (DOCX 75 kb)

References

  1. 1.
    King, M. T., Stockler, M. R., Butow, P., O’Connell, R., Voysey, M., Oza, A. M., et al. (2014). Development of the measure of ovarian symptoms and treatment concerns: Aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. International Journal of Gynecological Cancer, 24(5), 865–873.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 66(1), 7–30. doi: 10.3322/caac.21332.Google Scholar
  3. 3.
    American Cancer Society (2013). Cancer facts & figures 2013. In American Cancer Society (Ed.). Atlanta.Google Scholar
  4. 4.
    Friedlander, M. L., & King, M. T. (2013). Patient-reported outcomes in ovarian cancer clinical trials. Annals of Oncology, 24(suppl 10), x64–x68.CrossRefPubMedGoogle Scholar
  5. 5.
    Hess, L. M., & Stehman, F. B. (2012). State of the science in ovarian cancer quality of life research: A systematic review. International Journal of Gynecological Cancer, 22(7), 1273–1280. doi: 10.1097/IGC.0b013e318263f02e.CrossRefPubMedGoogle Scholar
  6. 6.
    Chan, A. W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., et al. (2013). SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. British Medical Journal, 8(346), e7586.CrossRefGoogle Scholar
  7. 7.
    Calvert, M., Kyte, D., von Hildebrand, M., King, M., & Moher, D. (2015). Putting patients at the heart of health-care research. The Lancet, 385(9973), 1073–1074.CrossRefGoogle Scholar
  8. 8.
    International Committee of Medical Journal Editors (2016). Clinical Trial Registration. http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. Accessed 6 April 2016.
  9. 9.
    Kyte, D., Duffy, H., Fletcher, B., Gheorghe, A., Mercieca-Bebber, R., King, M., et al. (2014). Systematic evaluation of the patient reported outcome (PRO) content of clinical trial protocols. PLoS One, 9(10), e110229.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Calvert, M., Kyte, D., Duffy, H., Gheorghe, A., Mercieca-Bebber, R., Ives, J., et al. (2014). Patient reported outcome (PRO) assessment in clinical trials: A systematic review of guidance for trial protocol writers. PLoS One, 9(10), e110216.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., et al. (2013). SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Annals of Internal Medicine, 158(3), 200–207.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    European Medicines Agency Oncology Working Party (2014). Draft Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies.Google Scholar
  13. 13.
    Food and Drug Administration (2009). Guidance for industry: Patient-reported outcome measures—Use in medical product development to support labeling claims.Google Scholar
  14. 14.
    Kyte, D., Reeve, B. B., Efficace, F., Haywood, K., Mercieca-Bebber, R., King, M. T., et al. (2016). International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. Quality of Life Research, 25(2), 359–362.CrossRefPubMedGoogle Scholar
  15. 15.
    Patrick, D. L., Guyatt, G. H., Acquadro, C., & Cochrane Patient Reported Outcomes Methods Group. (2011). Chapter 17: Patient-reported outcomes. In J. Higgins & S. Green (Eds.), Cochrane handbook for systematic reviews of interventions (Vol. 5.1.0.). London: The Cochrane Collaboration.Google Scholar
  16. 16.
    Aaronson, N. K. (1990). Quality of life research in cancer clinical trials: A need for common rules and language. Oncology, 4(5), 59–66.PubMedGoogle Scholar
  17. 17.
    Kyte, D., Ives, J., Draper, H., Keeley, T., & Calvert, M. (2013). Inconsistencies in quality of life data collection in clinical trials: A potential source of bias? Interviews with research nurses and trialists. PLoS One, 8(10), e76625. doi: 10.1371/journal.pone.0076625.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Mercieca-Bebber, R., Palmer, M., Brundage, M., Calvert, M., Stockler, M., & King, M. (2015). Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review. BMJO. doi: 10.1136/bmjopen-2015-010938.
  19. 19.
    Kyte, D., Draper, H., & Calvert, M. (2013). Patient-reported outcome alerts: Ethical and logistical considerations in clinical trials. JAMA, 310(12), 1229–1230.CrossRefPubMedGoogle Scholar
  20. 20.
    Kyte, D., Ives, J., Draper, H., & Calvert, M. (2016). Management of patient-reported outcome (PRO) alerts in clinical trials: A Cross sectional survey. PLoS One, 11(1), e0144658.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Skogvoll, E., & Kramer-Johansen, J. (2013). Publication of clinical trial protocols—what can we learn? Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 21, 12.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Weston, J., Dwan, K., Altman, D., Clarke, M., Gamble, C., Groves, T., et al. (2015). Selective reporting in clinical trials—An examination of discrepancy rates in pre-specified and reported outcomes in articles submitted to the BMJ. Trials, 16(2), 1. doi: 10.1186/1745-6215-16-s2-o72.Google Scholar
  23. 23.
    Schandelmaier, S., Conen, K., von Elm, E., You, J. J., Blumle, A., Tomonaga, Y., et al. (2015). Planning and reporting of quality-of-life outcomes in cancer trials. Annals of Oncology, 26(9), 1966–1973.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., et al. (2014). Reducing waste from incomplete or unusable reports of biomedical research. The Lancet, 383(9913), 267–276.CrossRefGoogle Scholar
  25. 25.
    Friedlander, M., Mercieca-Bebber, R., & King, M. (2016). Patient reported outcomes in ovarian cancer clinical trials—Lost opportunities and lessons learned. Annals of Oncology, 27(S1), i66–i71.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Central Clinical School, Sydney Medical SchoolUniversity of SydneySydneyAustralia
  2. 2.Quality of Life Office, Psycho-oncology Co-operative Research Group, School of PsychologyUniversity of SydneySydneyAustralia
  3. 3.NHMRC Clinical Trials CentreUniversity of SydneySydneyAustralia
  4. 4.Australian New Zealand Gynecological Oncology Group (ANZGOG)CamperdownAustralia
  5. 5.Institute of Applied Health ResearchUniversity of BirminghamBirminghamUK

Personalised recommendations